SEARCH

SEARCH BY CITATION

References

  • 1
    Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 3186980.
  • 2
    Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Váradi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 2115866.
  • 3
    Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Váradi K, Schwarz HP, Tans G. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 278528.
  • 4
    Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 25528.
  • 5
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 647.
  • 6
    Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A, Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397402.
  • 7
    Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 10048.
  • 8
    Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. J Thromb Haemost 2010; 8: 44553.
  • 9
    de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 12716.
  • 10
    Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 64350.
  • 11
    Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A. “Pseudo homozygous” activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996; 75: 4226.
  • 12
    Brugge JM, Simioni P, Bernardi F, Tormene D, Lunghi B, Tans G, Pagnan A, Rosing J, Castoldi E. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost 2005; 3: 2695702.
  • 13
    Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005; 106: 23635.
  • 14
    Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 15527.
  • 15
    de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83: 57782.
  • 16
    Mingozzi F, Legnani C, Lunghi B, Scanavini D, Castoldi E, Palareti G, Marchetti G, Bernardi F. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers. Thromb Haemost 2003; 89: 9839.
  • 17
    Bossone A, Cappucci F, D’Andrea G, Brancaccio V, Cibelli G, Iannaccone L, Grandone E, Margaglione M. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation. Haematologica 2003; 88: 2869.
  • 18
    Scanavini D, Girelli D, Lunghi B, Martinelli N, Legnani C, Pinotti M, Palareti G, Bernardi F. Modulation of factor V levels in plasma by polymorphisms in the C2 domain. Arterioscler Thromb Vasc Biol 2004; 24: 2006.
  • 19
    de Visser MC, van Hylckama Vlieg A, Tans G, Rosing J, Dahm AE, Sandset PM, Rosendaal FR, Bertina RM. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 148894.
  • 20
    Nicolaes GA, Thomassen MC, van Oerle R, Hamulyák K, Hemker HC, Tans G, Rosing J. A prothrombinase-based assay for detection of resistance to activated protein C. Thromb Haemost 1996; 76: 40410.
  • 21
    Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306–>Thr) associated with resistance to activated protein C. Blood 1998; 91: 11404.
  • 22
    Mumford AD, McVey JH, Morse CV, Gomez K, Steen M, Norstrøm EA, Tuddenham EG, Dahlbäck B, Bolton-Maggs PH. Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 2003; 123: 496501.
  • 23
    Castoldi E, Duckers C, Radu C, Spiezia L, Rossetto V, Tagariello G, Rosing J, Simioni P. Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma. J Thromb Haemost 2011; 9: 95968.
  • 24
    Ozawa T, Niiya K, Ejiri N, Sakuragawa N. A novel polymorphism in exon 10 of the factor V gene inducing an amino acid replacement of arginine to lysine at codon 485. Thromb Haemost 1997; 78: 141920.
  • 25
    Hiyoshi M, Arnutti P, Prayoonwiwat W, Nathalang O, Suwanasophon C, Kokaseam R, Hashimoto S, Takubo T, Tagawa S, Fukui M, Tatsumi N. A polymorphism nt 1628G–>A (R485K) in exon 10 of the coagulation factor V gene may be a risk factor for thrombosis in the indigenous Thai population. Thromb Haemost 1998; 80: 7056.
  • 26
    Le W, Yu JD, Lu L, Tao R, You B, Cai X, Cao WJ, Huang W, He RM, Zhu DL, Chen Z, Gong LS. Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population. Clin Genet 2000; 57: 296303.
  • 27
    Montefusco MC, Duga S, Asselta R, Malcovati M, Peyvandi F, Santagostino E, Mannucci PM, Tenchini ML. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood 2003; 102: 32106.
  • 28
    Lunghi B, Castoldi E, Mingozzi F, Bernardi F, Castaman G. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. Blood 1998; 92: 14634.
  • 29
    Vos HL. Inherited defects of coagulation Factor V: the thrombotic side. J Thromb Haemost 2006; 4: 3540.
  • 30
    Lunghi B, Scanavini D, Girelli D, Legnani C, Bernardi F. Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels? J Thromb Haemost 2005; 3: 4156.
  • 31
    Brozovic M, Chakrabarti R, Stirling Y, Fenton S, North WR, Meade TW. Factor V in an industrial population. Br J Haematol 1976; 33: 54350.
  • 32
    Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V Leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000; 20: 13826.
  • 33
    Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyák K, ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 12531.
  • 34
    Heit JA, Sobell JL, Li H, Sommer SS. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005; 3: 30511.
  • 35
    Castoldi E, Kalafatis M, Lunghi B, Simioni P, Ioannou PA, Petio M, Girolami A, Mann KG, Bernardi F. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998; 80: 4036.
  • 36
    Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103: 41739.
  • 37
    Kostka H, Siegert G, Schwarz T, Gehrisch S, Kuhlisch E, Schellong S, Jaross W. Frequency of polymorphisms in the B-domain of factor V gene in APC-resistant patients. Thromb Res 2000; 99: 53947.
  • 38
    Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A 1987; 84: 484650.